Enzon Pharmaceuticals, Inc. (ENZN) Reports Q4 Loss of $0.10

Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) reported Q4 EPS of ($0.10), versus ($0.16) reported last year. Revenue from royalties for the quarter came in at $9.8 million, versus $10.6 million reported last year.

For earnings history and earnings-related data on Enzon Pharmaceuticals, Inc. (ENZN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Genco rejects Diana Shipping bid, calls offer below NAV
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'